SCHEMBL17440329

SCHEMBL17440329

BrC1=CCC(c2ccccc2)CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC18A3 Q16572 2/20 0.41
SIGMAR1 Q99720 1/20 0.41
SRD5A1 P18405 1/20 0.40
GRIN2B Q13224 2/20 0.37
ADRA1A P35348 2/20 0.37
DAPK3 O43293 1/20 0.37
JAK2 O60674 1/20 0.37
CSF1R P07333 1/20 0.37
RET P07949 1/20 0.37
PRKACA P17612 1/20 0.37
LTK P29376 1/20 0.37
GRK5 P34947 1/20 0.37
KDR P35968 1/20 0.37
MAP2K2 P36507 1/20 0.37
MAPK8 P45983 1/20 0.37
CSNK1A1 P48729 1/20 0.37
CDK8 P49336 1/20 0.37
CLK2 P49760 1/20 0.37
GSK3A P49840 1/20 0.37
GSK3B P49841 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17440328 1.00 SLC18A3 (0.41) SLC18A3SIGMAR1SRD5A1GRIN2BADRA1A
SCHEMBL6171915 0.79 SLC18A3 (0.37) SLC18A3SIGMAR1SRD5A1GRIN2BADRA1A
SCHEMBL25073357 0.76 SLC18A3 (0.41) SLC18A3SIGMAR1SRD5A1GRIN2BADRA1A
SCHEMBL9876026 0.76 SRD5A1 (0.43) SLC18A3SIGMAR1SRD5A1GRIN2BADRA1A
SCHEMBL6740701 0.76 SLC18A3 (0.41) SLC18A3SIGMAR1SRD5A1GRIN2BADRA1A
SCHEMBL24105190 0.76 SLC18A3 (0.41) SLC18A3SIGMAR1SRD5A1GRIN2BADRA1A
SCHEMBL9372709 0.76 GAA (0.41) SLC18A3SIGMAR1SRD5A1GRIN2BADRA1A
SCHEMBL29060987 0.73 CYP2C9 (0.40) MAPTAKR1C3POLBKDM4EHPGD
SCHEMBL9517298 0.72 DRD3 (0.41) SLC18A3SIGMAR1SRD5A1GRIN2BADRA1A
SCHEMBL14789289 0.72 SLC18A3 (0.37) SLC18A3SIGMAR1SRD5A1GRIN2BADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190055280-A1 TRANSITION METAL-BASED SELECTIVE FUNCTIONALIZATION OF CHALCOGENS IN BIOMOLECULES NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2019-02-21 US disclosed
EP-3169319-A2 TRANSITION METAL-BASED SELECTIVE FUNCTIONALIZATION OF CHALCOGENS IN BIOMOLECULES Massachusetts Institute Of Technology (US) 2017-05-24 EP disclosed
WO-2016011107-A2 TRANSITION METAL-BASED SELECTIVE FUNCTIONALIZATION OF CHALCOGENS IN BIOMOLECULES MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2016-01-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190055280-A1 TRANSITION METAL-BASED SELECTIVE FUNCTIONALIZATION OF CHALCOGENS IN BIOMOLECULES SCLY, SELENOI, PTMS SLC18A3 1297/4885SIGMAR1 1890/4885SRD5A1 3538/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.